The stem cell biotechnology firm NovelStem International Corporation has launched arbitration proceedings against NetCo Partners to maximize value from legacy entertainment publishing assets. Omni Bridgeway has been announced as the litigation funder backing NovelStem’s ambitions.
An LFJ Conversation with Michael Kelley, Partner, Parker Poe
The stem cell biotechnology firm NovelStem International Corporation has launched arbitration proceedings against NetCo Partners to maximize value from legacy entertainment publishing assets. Omni Bridgeway has been announced as the litigation funder backing NovelStem’s ambitions.
NewsFileCorp.com’s press release on the developing matter outlines that NovelStem’s Chairman plans to extract value from their 50% stake in Netco Partners. Netco’s publishing arm, Net Force, has generated over $24M in total revenue since inception, and NovelStem anticipates substantial returns may be captured across digital, media and entertainment pillars.
NovelStem’s Chairman further details that litigation investment by Omni Bridgeway is enabling flexibility for broader investment in NewStem Ltd. Over the coming months, NovelStem plans to brief investors on the success of the NetCo Partners litigation and growth of NewStem Ltd.’s new investment dollars.
